Scribd
Upload
368 views1 page

Comparison of Clinical Trial Phases

Phase I clinical trials involve small groups of people to determine the safety and side effects of a new drug. Phase II trials provide initial evidence that the drug works as intended in specific groups. Phase III trials involve much larger groups to confirm effectiveness, monitor side effects, and compare against standard treatments. Phase IV trials collect additional data on a drug's risks and benefits over time in diverse real-world populations after FDA approval.

Uploaded by

Chitosan Polymer
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
368 views1 page

Comparison of Clinical Trial Phases

Phase I clinical trials involve small groups of people to determine the safety and side effects of a new drug. Phase II trials provide initial evidence that the drug works as intended in specific groups. Phase III trials involve much larger groups to confirm effectiveness, monitor side effects, and compare against standard treatments. Phase IV trials collect additional data on a drug's risks and benefits over time in diverse real-world populations after FDA approval.

Uploaded by

Chitosan Polymer
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

COMPARISON OF CLINICAL TRIAL PHASES

PHASE I PHASE II PHASE III PHASE IV


OBJECTIVES: Determine the metabolic and Evaluate effectiveness, Obtain additional information Monitor ongoing safety in
pharmacological actions and determine the short-term side about the effectiveness on large populations and identify
the maximally tolerated dose effects and identify common clinical outcomes and evaluate additional uses of the agent
risks for a specific population the overall risk-benefit ratio in a that might be approved by the
and disease demographically diverse sample FDA

u
FACTORS -Bioavailability -Bioavailability -Drug-disease interactions -Epidemiological data

ed
TO BE -Bioequivalence -Drug-disease interactions -Drug-drug interactions -Efficacy and safety within
IDENTIFIED: -Dose proportionality -Drug-drug interactions -Dosage intervals large, diverse populations
-Metabolism -Efficacy at various doses -Risk-benefit information -Pharmacoeconomics

a.
-Pharmacodynamics -Pharmakodynamics -Efficacy and safety for
-Pharmacokinetics -Pharmakokinetics subgroups

m
-Patient safety
DATA FOCUS: -Vital signs -Dose response and tolerance -Laboratory data -Efficacy

ar
-Plasma and serum levels -Adverse events -Efficacy -Pharmacoeconomics
-Adverse events -Efficacy -Adverse events -Epidemiology

Ph
-Adverse events
DESIGN -Single, ascending dose tiers -Placebo controlled comparisons -Randomized -Uncontrolled
FEATURES: -Unblinded -Active controlled comparisons -Controlled -Observational
-Uncontrolled -Well-defined entry criteria -2-3 treatment arms
U
-Broader eligibility criteria
DURATION: Up to 1 month Several months Several years Ongoing (following FDA
D
approval)
POPULATION: Healthy volunteers or Individuals with target disease Individuals with target disease Individuals with target disease,
N

individuals with the target as well as new age groups,


G

disease (such as cancer or genders, etc.


HIV)
SAMPLE 20 to 80 200 to 300 Hundreds to thousands Thousands
SIZE:
EXAMPLE: Study of a single dose of Drug Double-blind study evaluating Study of Drug X vs. standard Study of economic benefit of
X in normal subjects safety and efficacy of Drug X treatment in hypertension study newly-approved Drug X vs.
vs. placebo in patients with standard treatment for
hypertension hypertension

You might also like